Clinical efficacy of a new angiotensin II type 1 receptor blocker, pratosartan, in hypertensive patients

Hypertension Research

Volumn 31, Issue 2, 2008, Pages 281-287

  Ogihara, Toshio ^a   Saruta, Takao ^b   Shimamoto, Kazuaki ^c   Matsuoka, Hiroaki ^d   Rakugi, Hiromi ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b KEIO UNIVERSITY   (Japan)

^c SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Angiotensin II receptor blocker; Cholesterol; Hypertension; Pratosartan; Uric acid

Indexed keywords

ALKALINE PHOSPHATASE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CILNIDIPINE; DIURETIC AGENT; HYDROCHLOROTHIAZIDE; INDAPAMIDE; MANIDIPINE; MEPIRODIPINE; NIFEDIPINE; NILVADIPINE; PLACEBO; PRATOSARTAN; TRICHLORMETHIAZIDE; UNCLASSIFIED DRUG; URIC ACID;

ADULT; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERURICEMIA; MALE; MONOTHERAPY; MULTICENTER STUDY; OPEN STUDY; PROTEINURIA; SIDE EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; URIC ACID BLOOD LEVEL;

ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BLOOD GLUCOSE; CHOLESTEROL; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; IMIDAZOLES; MALE; MIDDLE AGED; TETRAZOLES; URIC ACID;

EID: 41549154598     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1291/hypres.31.281     Document Type: Article

References (36)

1. Yanagisawa T, Ueyama N, Kawai T, et al: 4,5,6,7-Tetrahydro-8-oxo-cycloheptimidazoles: a new class of potent non-peptide angiotensin II receptor antagonists. Bioorg Med Chem Lett 1993; 3: 1559-1564.
2. Wong PC, Timmermans PB: Nonpeptide angiotensin II receptor antagonists: insurmountable angiotensin II antagonism of EXP3892 is reversed by the surmountable antagonist DuP 753. J Pharmacol Exp Ther 1991; 258: 49-57.
3. ATP channels. J Cardiovasc Pharmacol 2000; 35: 457-467.
4. Mochizuki S, Sato T, Furuta K, et al: Pharmacological properties of KT3-671, a novel nonpeptide angiotensin II receptor antagonist. J Cardiovasc Pharmacol 1995; 25: 22-29.
5. Patterson D, Webster J, McInnes G, Brady A, MacDonald T: The effects of KT3-671. a new angiotensin II (AT 1) receptor blocker in inild to moderate hypertension. Br J Clin Pharmacol 2003; 56: 513-519.
6. Nakashima M, Uematsu T, Kosuge K, Kanamaru M: Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects. Eur J Clin Pharmacol 1992; 42: 333-335.
7. Tsunoda K, Abe K, Hagino T, et al: Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension. Am J Hypertens 1993; 6: 28-32.
8. Hoieggen A, Aldeman MH, Kjeldsen SE, et al: The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004; 65: 1041-1049.
9. Daskalopoulou SS, Tzovaras V, Mikhailidis DP, Elisaf M: Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia. Curr Pharm Des 2005; 11: 4161-4175.
10. Saito M, Kawai M, Kobayashi Y, et al: Uricosuric effect of angiotensin II receptor antagonists in the patients with normal renal function. Jpn J Clin Pharmacol Ther 2003; 34: 37-42 (in Japanese).
11. Kagan A, Harris BR, Winkelstein W Jr, et al: Epidemiologic studies on coronary heart disease and stroke in Japanese men living in Japan, Hawaii and California: demographic, physical, dietary and biochemical characteristics. J Chronic Dis 1974; 27: 345-364.
12. Sweet CS, Bradstreet DC, Berman RS, Jallard N, Saenz A, Weidler DJ: Pharmcodynamic activity of intravenous E-3174, an angiotensin II antagonist, in patients with essential hypertension. Am J Hypertens 1994; 7: 1035-1040.
13. Benson SC, Pershadsingh HA, Ho CI, et al: Identification of telmisartan as an angiotensin II receptor antagonist with selective PPAR gamma-modulating activity. Hypertension 2004; 43: 993-1002.
14. Derosa G, Cicero AFG, D'Angelo A, et al: Telmisartan and irbesartan therapy in type 2 diabetic patients treated with rosiglitazone: effects on insulin-resistance, leptin and tumor necrosis factor-α. Hypertens Res 2006; 29: 849-856.
15. Yoshinaga K, Abe K, Iimura O, et al: Efficacy and safety of MK-954 (losartan potassium), a new angiotensin II receptor antagonist, in patients with essential hypertension. J Clin Therap Med 1994; 10 (Suppl 6): 49-78 (in Japanese).
16. Yoshinaga K, Abe K, Iimura O, et al: Effect of MK-954 (losartan potassium), a new angiotensin II receptor antagonist, on essential hypertension - combination therapy with thiazides -. J Clin Therap Med 1994; 10 (Suppl 6): 79-101 (in Japanese).
17. Arakawa K, Iimura O, Abe K, et al: Hypotensive effect and safety of TCV-116 (candesartan cilexetil), a new angiotensin II receptor antagonist, in patients with essential hypertension - clinical late phase II study -. J Clin Therap Med 1996; 12 (Suppl 11): 2231-2266 (in Japanese).
18. Arakawa M, Gejyo F, Nakagawa Y, et al: Hypotensive effect and safety of TCV-116 (candesartan cilexetil), a new angiotensin II receptor antagonist, combination therapy with thiazides on essential hypertension - clinical late phase II study -. J Clin Therap Med 1996; 12 (Suppl 11): 2267-2296 (in Japanese).
19. Saruta T, Suzuki H, Nobutomo K: Efficacy and safety of candesartan cilexetil (TCV- 116) on essential hypertension in combination therapy with calcium antagonists. J Clin Therap Med 1996; 12 (Suppl 11): 2297-2322 (in Japanese).
20. Yoshinaga K, Ogihara T, Iimura O, et al: Clinical evaluation of CGP 48933 (valsartan), a new angiotensin II receptor antagonist, in patients with essential hypertension. J Clin Therap Med 1998; 14 (Suppl 10): 1787-1814 (in Japanese).
21. Yoshmaga K, Iimura O, Abe K, et al: Clinical evaluation of CGP 48933 (valsartan), a new angiotensin II receptor antagonist, in patients with essential hypertension - combination therapy with diuretics -. J Clin Therap Med 1998; 14 (Suppl 10): 1815-1835 (in Japanese).
22. Yoshinaga K, Arakawa K, Iimura O, et al: Clinical evaluation of CGP 48933 (valsartan), a new angiotensin II receptor antagonist, in patients with essential hypertension- - combination therapy with calcium antagonists -. J Clin Therap Med 1998; 14 (Suppl 10): 1837-1857 (in Japanese).
23. 1 receptor antagonist, in patients with mild-to-moderate essential hypertension. Jpn Pharmacol Ther 2002; 30 (Suppl 1): 103-119 (in Japanese).
24. 1 receptor antagonist, with calcium antagonists or diuretics in patients with mild-to-moderate essential hypertension. Jpn Pharmacol Ther 2002; 30 (Suppl 1): 121-138 (in Japanese).
25. Arakawa K, Shimamoto K, Abe K, et al: The optimal dose of CS-866 (olmesartan medoxomil), a novel angiotensin II receptor antagonist, in patients with mild-to-moderate essential hypertension - late phase II study -. J Clin Therap Med 2003; 19: 1001-1028 (in Japanese).
26. Hirai A, Ito K: Clinical evaluation of an angiotensin II receptor antagonist in essential hypertensive patients - a phase III open trial with calcium channel blocker, or hydrochlorothizide -. J Clin Therap Med 2003; 20: 161-187 (in Japanese).
27. Chobanian AV, Bakris GL, Black HR, et al, The National High Blood Pressure Education Program Coordination Committee: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. JAMA 2003; 289: 2560-2572.
28. Guidelines Committee: 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-1053.
29. Japanese Society of Hypertension: Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2004). Hypertens Res 2006; 29 (Suppl): S1-S105.
30. Iwanaga T, Sato M, Maeda T, Ogihara T, Tamai I: Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter URATI. J Pharmacol Exp Ther 2006; 320: 211-217.
31. Viazzi F, Parodi D, Leoncini G, et al: Serum uric acid and target organ damage in primary hypertension. Hypertension 2005; 45: 991-996.
32. Iwashima Y, Horio T, Kamide K, Rakugi H, Ogihara T, Kawano Y: Uric acid, left ventricular mass index, and risk of cardiovascular disease in essential hypertension. Hypertension 2006; 47: 195-202.
33. Enomoto A, Kimura H, Chairoungdua A, et al: Molecular identification of a renal urate-anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-452.
34. Alderman MH, Cohen H, Madhavan S, Kivlighn S: Serum uric acid and cardiovascular events in successfully treated hypertensive patients. Hypertension 1999; 34: 144-150.
35. Franse LV, Pahor M, Di Bari M, et al: Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program (SHEP). J Hypertens 2000; 18: 1149-1154.
36. Losartan Trial Investigators, Manolis AJ, Grossman E, Jelakovic B, et al: Effects of losartan and candesartan monotherapy and losartan/ hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Clin Ther 2000; 22: 1186-1203.